Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma

2011134 citationsJournal Article

Authors

Alfredo Berruti · University of Turin

Paola Sperone · Ospedale San Luigi Gonzaga

Annamaria Ferrero · University of Turin

Antonina Germano · Ospedale San Luigi Gonzaga

Arianna Ardito · Ospedale San Luigi Gonzaga

Adriano Massimiliano Priola · University of Turin

Silvia De Francia ·

Abstract

Despite the in vitro activity, sorafenib plus weekly paclitaxel is an inactive salvage treatment in patients with advanced ACC and should not be recommended.

Topics & Keywords

Adrenal and Paraganglionic Tumors Cancer, Hypoxia, and Metabolism Pituitary Gland Disorders and Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: European Journal of Endocrinology

Volume 166, Issue 3, pp. 451-458

DOI: 10.1530/eje-11-0918

Field-Weighted Citation Impact: 8.03